CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc's Leverage Ratio

XFOR's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 5.19%, Leverage Ratio fell to 106.19, a new company high.

Within Biotechnology & Pharmaceuticals industry in the first quarter 2024, 70 other companies have achieved lower Leverage Ratio than X4 Pharmaceuticals Inc in the I Quarter 2024. While Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 2410 to 2918 .

Explain Leverage Ratio?
Who are XFOR Customers?
What are XFOR´s Total Liabilities?


XFOR Leverage Ratio (Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Total Liabilities Change 36.94 % 107.53 % 110.23 % 46.62 % 55.42 %
Leverage Ratio MRQ 106.19 1.55 1.55 1.38 1.08
XFOR's Total Ranking # 2918 # 2410 # 1726 # 2170 #
Seq. Equity Change -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Total Liabilities Change 5.19 % -0.13 % 46.35 % -10.93 % 59.42 %



Leverage Ratio first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 71
Healthcare Sector # 536
Overall Market # 2918


Leverage Ratio Statistics
High Average Low
106.19 5.16 0.24
(Mar 31 2024)   (Dec 31 2019)




Financial Statements
X4 Pharmaceuticals Inc's Equity $ 1 Millions Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Total Liabilities $ 110 Millions Visit XFOR's Balance sheet
Source of XFOR's Sales Visit XFOR's Sales by Geography


Cumulative X4 Pharmaceuticals Inc's Leverage Ratio

XFOR's Leverage Ratio for the trailling 12 Months

XFOR Leverage Ratio

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Total Liabilities TTM Growth 36.94 % 107.53 % 110.23 % 46.62 % 55.42 %
Leverage Ratio TTM 2.08 1.38 1.2 1.16 1.06
Total Ranking TTM # 2629 # 7 # 5 # 32 #
Seq. Equity TTM Growth -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Total Liabilities TTM Growth 5.19 % -0.13 % 46.35 % -10.93 % 59.42 %


On the trailing twelve months basis Due to the net new borrowings of 5.19% during the trailing twelve months finishing in the I Quarter 2024, cumulativeLeverage Ratio improved to 2.08, above the X4 Pharmaceuticals Inc's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 63, during the past 12 months, other companies have achieved lower Leverage Ratio than X4 Pharmaceuticals Inc. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the I Quarter 2024, compared to the prior period, from 7 to 2629.

Explain Leverage Ratio?
Who are XFOR Customers?
What are XFOR´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 64
Healthcare Sector # 477
Within the Market # 2629


trailing twelve months Leverage Ratio Statistics
High Average Low
2.11 0.77 0.31
(Mar 31 2024)   (Jun 30 2020)




Companies with similar Leverage Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Leverage RatioMar 31 2024 MRQ Total LiabilitiesMar 31 2024 MRQ Equity
X4 Pharmaceuticals Inc  106.19 $ 110.013  Millions$ 1.036  Millions
Inhibrx Inc   23.71 $ 274.331  Millions$ 11.568  Millions
Fennec Pharmaceuticals Inc   21.96 $ 66.179  Millions$ 3.014  Millions

Date modified: 2024-05-08T15:34:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com